Results 51 to 60 of about 12,775 (197)

Interventions for preventing oral mucositis for patients with cancer receiving treatment [PDF]

, 2003
Background: Treatment of cancer with chemotherapy is becoming increasingly more effective but is associated with short and long-term side effects. Oral side effects remain a major source of illness despite the use of a variety of agents to prevent them ...
Bryan, Gemma, Clarkson, Jan E., Furness, Susan, Glenny, Anne-Marie, Khalid, Tasneem, Littlewood, Anne, McCabe, Martin G., Meyer, Stefan, Worthington, Helen V.   +8 more
core   +3 more sources

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Consistency between direct trial evidence and Bayesian Mixed Treatment Comparison: Is head-to-head evidence always more reliable? [PDF]

Objectives: This study aims to highlight the benefits of Bayesian mixed treatment comparison (MTC), within a case study of the efficacy of three treatments (pegfilgrastim, filgrastim and lenograstim) for the prevention of febrile neutropenia (FN ...
Akehurst, R., Cooper, K.L., Madan, J., Stevenson, M.D., Whyte, S.   +4 more
core   +3 more sources

Manufacturing Barriers to Biologics Competition and Innovation [PDF]

, 2016
As finding breakthrough small-molecule drugs gets harder, drug companies are increasingly turning to “large molecule” biologics. Although biologics represent many of the most promising new therapies for previously intractable diseases, they are extremely
Price, W. Nicholson, II, Rai, Arti K.
core   +2 more sources

Toxic Epidermal Necrolysis after Pemetrexed and Cisplatin for Non-Small Cell Lung Cancer in a Patient with Sharp Syndrome [PDF]

, 2012
Background: Pemetrexed is an antifolate drug approved for maintenance and second-line therapy, and, in combination with cisplatin, for first-line treatment of advanced nonsquamous non-small cell lung cancer.
Aguiar D, Azukizawa H, Barlési F, Bastuji-Garin S, Belani CP, Bosch-Barrera J, Bracke A, Cohen MH, Cornelia Then, Daniel Müller, Del Pozzo-Magana BR, Fuld AD, Grader-Beck T, Harr T, Iung, Jobst C. von Einem, Kardaun SH, Lopes G, Martin Reincke, Michael J. Flaig, Mockenhaupt M, Rudolf M. Huber, Schneck J, Seiwert TY, Shih C, Tan SK, Tummino C, Vitiello M, Yun SJ   +28 more
core   +1 more source

Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review summarizes recent advances in nanoparticle‐ and cell‐mediated OVs delivery strategies that improve biodistribution and tumor targeting while limiting immune clearance. It also examines combination approaches that enhance therapeutic efficacy through tumor microenvironment modulation or immune activation, thereby overcoming immunosuppression
Sikan Jin, Yi Zhang, Ziling Zhou, Yaqi Zhang, Ting Yu, Rui Xu, Lin Xu, Jidong Zhang, Longze Zhang, Shan Yang, Xianyao Wang   +10 more
wiley   +1 more source

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors [PDF]

, 2012
BACKGROUND Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as ...
Anasetti, Claudio, Anderlini, Paolo, Bensinger, William I., Bredeson, Christopher, Carter, Shelly L., Confer, Dennis L., Couban, Stephen, Cutler, Corey S., Ehninger, Gerhard, Horowitz, Mary M., Johnston, Laura, Khan, Shakila P., Lee, Stephanie J., Leitman, Susan F., Logan, Brent R., Maziarz, Richard T., McCarty, John M., Mineishi, Shin, Porter, David L., Pulsipher, Michael A., Rowley, Scott D., Waller, Edmund K., Weisdorf, Daniel J., Westervelt, Peter, Wingard, John R., Woolfrey, Ann   +25 more
core   +5 more sources

A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation

Italian Journal of Pediatrics, 2018
Background To compare the effect of xinruibai (Pegfilgrastim) and filgrastim injections on white blood cell and platelet (PLT) recovery, adverse events, post-operative complications, and cost effectiveness after allogeneic hematopoietic stem cell ...
Qixiang Ye, Hebi Jiang, Hua Jiang
doaj   +1 more source

Immunocompromised Status Definition in Observational Studies Using Electronic Health Records: A Scoping Review and a Proposal for a Phenotype Identification Algorithm

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Immunocompromised individuals experience an impaired immune function due to conditions that might be either congenital or acquired over the course of their lives. Epidemiological studies often rely on clinical definitions which, in some cases, benefit from being translated into machine‐readable algorithms for application to electronic health ...
Judit Riera‐Arnau, Nicoletta Luxi, Fabio Riefolo, Martín Solorzano, Irene Pazos, Elena Ballarín, Lise Skovgaard Svingel, Lorenzo Chiusaroli, Elisa Martín‐Merino, Elisa Barbieri, María Lopez‐Lasanta, Sima Mohammadi, Denis Rotta, Alexandra Pacurariu, Catherine Cohet, Miriam Sturkenboom, Carlos E. Durán, on behalf of the SAFETY‐VAC study consortium, Carlos E. Durán, Miriam Sturkenboom, Judit Riera‐Arnau, Nicoletta Luxi, Olaf Klungel, Patrick Souverein, Sima Mohammadi, Fabio Riefolo, Irene Pazos, Rosa Gini, Davide Messina, Giuseppe Roberto, Carlo Giaquinto, Elisa Barbieri, Luca Stona, Felipe Villalobos, Martín Solorzano, Carlo Alberto Bissacco, Antonio Gimeno, Beatriz Poblador, Mercedes Aza, Aida Moreno, Alejandro Santos, Vera Ehrenstein, Lise Skovgaard Svingel, Benjamin Randeris Johannesen, Cécile Droz‐Perroteau, Laure Carcaillon‐Bentata, Anna‐Mija Tolppanen, Sirpa Hartikainen, Thuan Vo, Anne Paakinaho, Blair Rajamaki, Hedvig Nordeng, Saeed Hayati, Mahmoud Zidan, Juan José Carreras Martínez, Arantxa Urchueguía Fornes, Elisa Correcher Martínez, Javier Díez‐Domingo, Mar Martin, Patricia Garcia‐Poza, Airam de Burgos, Belén Castillo‐Cano, Elisa Martín‐Merino   +62 more
wiley   +1 more source

A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects

Drug Design, Development and Therapy, 2015
Liat Adar,1 Noa Avisar,1 Andreas Lammerich,2 Robert B Kleiman,3 Ofer Spiegelstein1 1R&D, Teva Pharmaceutical Industries Ltd, Netanya, Israel; 2Biosimilars Clinical Development, CPP Teva ratiopharm, Merckle GmbH, Ulm, Germany; 3Global Cardiology,
Adar L, Avisar N, Lammerich A, Kleiman RB, Spiegelstein O   +4 more
doaj